QUINCY, Mass., Nov. 16, 2026 — The National Organization for Rare Disorders (NORD®), the leading national nonprofit serving more than 30 million Americans with rare diseases, announced seven new requests for proposals (RFPs) totaling $452,000 in seed grant funding. These grants were funded by the Appendix Cancer/Pseudomyxoma Peritonei Research Foundation, a NORD Member patient organization; the Peutz-Jeghers syndrome community; the primary orthostatic tremor community; the Beckwith-Wiedemann syndrome community; the alveolar capillary dysplasia community; and the pheochromocytoma community.
The grants are part of NORD’s Rare Disease Research Grant Program, which provides early-stage funding to advance promising rare disease research. With fewer than 5% of approximately 10,000 known rare diseases having an FDA-approved therapy, this support is critical. Since 1989, NORD has invested more than $9 million in research grants to help move scientific discoveries forward.
This cycle, NORD is seeking proposals for the following rare diseases:
Appendix Cancer/Pseudomyxoma Peritonei (ACPMP) An extremely rare cancer of the appendix that typically starts in the appendix and frequently spreads to the abdominal cavity. This can lead to either a buildup of mucinous fluid in the abdomen known as pseudomyxoma peritonei or a condition referred to as peritoneal carcinomatosis.
Peutz-Jeghers Syndrome (PJS) A rare genetic condition characterized by the development of benign polyps in the stomach and intestines, or gastrointestinal tract, and distinctive dark spots on the skin and mucous membranes.
Primary Orthostatic Tremor A rare movement disorder characterized by a rapid tremor in the legs that occurs when standing and disappears partially or completely when an affected person is walking, sitting, or lying down.
Beckwith-Wiedemann Syndrome An overgrowth and cancer predisposition disorder resulting from various abnormalities affecting the proper expression of genes that control growth within a specific region of chromosome 11 (11p15.5).
Alveolar Capillary Dysplasia with Misalignment of Pulmonary Veins (ACDMPV) A rarely diagnosed, lethal developmental lung disorder in newborns that is present at birth and, in most cases, is caused by point mutations involving the FOXF1 gene.
Pheochromocytoma A rare tumor that develops in cells of the adrenal gland and is associated with ganglia of the sympathetic nervous system. Tumors can become cancerous and spread to other parts of the body.
Funding will be awarded to qualified researchers, based on scientific merit, to initiate scientific research studies or clinical trials with the potential to attract larger funding awards from agencies such as the National Institutes of Health (NIH), the U.S. Food and Drug Administration (FDA), or corporate sponsors. This early support helps expand promising projects into comprehensive, multiphase studies that can lead to new treatments for rare and complex diseases.
How to apply:
Applications are now open and will be accepted through Jan. 19, 2027, at 11:59 p.m. PT. Researchers at accredited academic institutions, hospitals, and nonprofit research centers, as well as early-career investigators, are encouraged to apply. Learn more and view application instructions here.
Applications will be subject to peer-review adjudication led by NORD’s Medical Advisory Committee and COE, a panel of volunteer rare disease medical experts.
About NORD’s Rare Disease Research Grant Program
Since 1989, NORD has awarded more than $9 million in research grants to advance scientific discovery for rare diseases that lack treatment and research funding. With fewer than 5% of the approximately 10,000 known rare diseases having an FDA-approved therapy, and the cost of developing a prescription medication reaching millions of dollars, early-stage funding plays a critical role in unlocking progress.
NORD’s grant program has jump-started critical rare disease research, supported numerous peer-reviewed publications, and contributed to the development of two FDA-approved treatments.
About the National Organization for Rare Disorders (NORD®)
Founded in 1983, the National Organization for Rare Disorders (NORD®) is a leading independent, nonpartisan nonprofit organization dedicated to improving the health and lives of more than 30 million Americans with rare diseases. In partnership with more than 350 disease-specific member patient organizations and 50 designated NORD® Rare Disease Centers of Excellence spanning more than 175 academic medical centers, research institutions, and children’s hospitals nationwide, NORD advances care, research, education, and advocacy to create a better future for people and families with rare diseases. Learn more at rarediseases.org.
Media Contact
Cheryl Herbert, Vice President, Marketing & Communications, [email protected]

